- Conditions
- Breast Cancer
- Interventions
- Docetaxel, Trastuzumab, Carboplatin, Bevacizumab, 5-Fluorouracil, Epirubicin, Cyclophosphamide
- Drug
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3,509 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 393
- States / cities
- Birmingham, Alabama • Decatur, Alabama • Huntsville, Alabama + 272 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–288
of 10,484
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Genital Neoplasms, Female, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pelvic Neoplasms, Peritoneal Neoplasms
- Interventions
- Gemcitabine, liposomal doxorubicin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab, VELCADE (Bortezomib), Dexamethasone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 498 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Los Angeles, California • Stamford, Connecticut + 14 more
- Conditions
- HIV Infections
- Interventions
- Saquinavir, Zidovudine, Zalcitabine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Sacramento, California • San Francisco, California + 17 more
- Conditions
- Eosinophilic Esophagitis (EoE)
- Interventions
- Oral Budesonide Suspension (OBS), Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 11 Years to 55 Years
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
- Conditions
- Breast Cancer, Hot Flashes
- Interventions
- gabapentin, antidepressant
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 162
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Augusta, Georgia + 101 more
- Conditions
- Soft Tissue Sarcoma
- Interventions
- Antineoplaston therapy (Atengenal + Astugenal)
- Drug
- Lead sponsor
- Burzynski Research Institute
- Other
- Eligibility
- 6 Months to 99 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2003
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- recombinant interferon alfa
- Biological
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2005
- U.S. locations
- 7
- States / cities
- Wichita, Kansas • New Orleans, Louisiana • Hackensack, New Jersey + 4 more
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma, Stage III Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer
- Interventions
- Filgrastim, Laboratory Biomarker Analysis, Pegfilgrastim, Topotecan Hydrochloride, Veliparib
- Biological · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 78
- States / cities
- Orange, California • Aurora, Colorado • Hartford, Connecticut + 56 more
- Conditions
- Influenza
- Interventions
- favipiravir, Placebo
- Drug
- Lead sponsor
- MDVI, LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 860 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Hunstville, Alabama • Hot Springs, Arkansas + 48 more
- Conditions
- Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma, Locally Advanced Gallbladder Carcinoma, Locally Advanced Intrahepatic Cholangiocarcinoma, Metastatic Ampulla of Vater Carcinoma, Metastatic Biliary Tract Carcinoma, Metastatic Extrahepatic Cholangiocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Stage III Ampulla of Vater Cancer AJCC v8, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Ampulla of Vater Cancer AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Ampulla of Vater Carcinoma, Unresectable Biliary Tract Carcinoma, Unresectable Extrahepatic Cholangiocarcinoma, Unresectable Gallbladder Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
- Interventions
- Biospecimen Collection, Cisplatin, Computed Tomography, Durvalumab, Gemcitabine, Magnetic Resonance Imaging, Pemigatinib, Survey Administration
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Interventions
- Quality-of-Life Assessment, Questionnaire Administration, Supportive Care
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Lumbar Disc Herniation
- Interventions
- SI-6603, Sham injection
- Drug
- Lead sponsor
- Seikagaku Corporation
- Industry
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 352 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 67
- States / cities
- Mobile, Alabama • Fountain Valley, California • La Jolla, California + 60 more
- Conditions
- Localized Stage I-III Esophageal Cancer, Gastroesophageal Junction Cancer
- Interventions
- nutritional and functional assessments
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more
- Conditions
- Tendonitis;Achilles
- Interventions
- Micronized DHACM, Saline Injection
- Biological · Drug
- Lead sponsor
- MiMedx Group, Inc.
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Carlsbad, California + 10 more
- Conditions
- Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Postmenopausal, Progesterone Receptor Positive, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
- Interventions
- Biopsy of Breast, Copanlisib, Laboratory Biomarker Analysis, Letrozole, Palbociclib, Pharmacological Study
- Procedure · Drug · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Lung Adenocarcinoma, Lung Large Cell Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8
- Interventions
- Carboplatin, Cisplatin, Computed Tomography, Durvalumab, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, Methoxyamine, Pemetrexed, Radiation Therapy
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 34
- States / cities
- Buena Park, California • Duarte, California • Irvine, California + 27 more
- Conditions
- Obesity, Diabetes Mellitus, Type 2
- Interventions
- Survodutide, Placebo
- Combination Product
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 755 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 34
- States / cities
- Anniston, Alabama • Phoenix, Arizona • Spring Valley, California + 31 more
- Conditions
- Allergic Conjunctivitis
- Interventions
- Dexamethasone, 0.4mg, Placebo plug with no drug
- Drug · Device
- Lead sponsor
- Ocular Therapeutix, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 6
- States / cities
- Colorado Springs, Colorado • Louisville, Kentucky • Raynham, Massachusetts + 3 more
- Conditions
- Stage 0 Breast Carcinoma, Breast Neoplasms, Stage I Breast Carcinoma, Stage II Breast Carcinoma, Stage III Breast Carcinoma
- Interventions
- Metformin, Omega-3 fatty acids
- Drug
- Lead sponsor
- Katherine D. Crew
- Other
- Eligibility
- 21 Years to 75 Years · Female only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Cancer
- Interventions
- Zoledronic Acid
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2013
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Solid Tumor, Solid Tumor, Adult, Solid Tumor, Unspecified, Adult
- Interventions
- Meaning Centered Psychotherapy for Latinos, Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale, Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients, Pre-assessment questionnaire
- Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2027
- U.S. locations
- 3
- States / cities
- New York, New York • The Bronx, New York
- Conditions
- Heterozygous Familial Hypercholesterolaemia
- Interventions
- AZD0780, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 473 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 19
- States / cities
- Garden Grove, California • San Diego, California • Miami Lakes, Florida + 16 more
- Conditions
- NonSegmental Vitiligo
- Interventions
- Povorcitinib, Placebo
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Fountain Valley, California + 25 more